GlaxoSmithKline (GSK) MIsses Q1 EPS Views on Lighter Revs

GlaxoSmithKline (NYSE: GSK) reported Q1 EPS of $0.42, $0.49 worse than the analyst estimate of $0.91. Revenue for the quarter came in at $10.49 million versus the consensus estimate of $10.88 million.

For earnings history and earnings-related data on GlaxoSmithKline (GSK) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Burry doubles down on Nebius short after stock surges 34% on earnings
• Pulmatrix (PULM) Reports Q2 Loss of $0.29
• Ackman adds Netflix, Visa and Mastercard in portfolio revamp